Therapeutic strategies in the early stages of Parkinson’s disease: a cross-sectional evaluation of 15 years’ experience with a large cohort of Romanian patients
József Attila Szász,1,2 Károly Orbán-Kis,1 Viorelia Adelina Constantin,2,3 Csongor Péter,1 István Bíró,1 István Mihály,1,2 Kinga Szegedi,2 Antal Balla,2 Szabolcs Szatmári1,2 1Uni...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2019
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/b5401913058d40abbaf589a699d9b6ee |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:b5401913058d40abbaf589a699d9b6ee |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:b5401913058d40abbaf589a699d9b6ee2021-12-02T04:55:54ZTherapeutic strategies in the early stages of Parkinson’s disease: a cross-sectional evaluation of 15 years’ experience with a large cohort of Romanian patients1178-2021https://doaj.org/article/b5401913058d40abbaf589a699d9b6ee2019-04-01T00:00:00Zhttps://www.dovepress.com/therapeutic-strategies-in-the-early-stages-of-parkinsons-disease-a-cro-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021József Attila Szász,1,2 Károly Orbán-Kis,1 Viorelia Adelina Constantin,2,3 Csongor Péter,1 István Bíró,1 István Mihály,1,2 Kinga Szegedi,2 Antal Balla,2 Szabolcs Szatmári1,2 1University of Medicine and Pharmacy, Târgu Mureş, Romania; 22nd Neurology Department, Târgu Mureş County Emergency Hospital, Târgu Mureş, Romania; 3Doctoral School, Victor Babes University of Medicine and Pharmacy, Timişoara, Romania Introduction: In patients older than 70 years there is no valid alternative to progressively introduced substitution therapy. The antiparkinsonian drugs introduced in the last decade to treat Parkinson’s disease, especially in its early phases, promised a comparable efficacy in reducing symptoms to levodopa. In younger patients and/or patients with mild symptoms we hoped to delay the motor complications by postponing the start of levodopa therapy. While these assumptions may not be true for all patients, probably the most important current challenge is the optimal starting moment of levodopa therapy. The aim of the study was to analyze the therapeutical choices during the early phase of Parkinson’s disease in the Neurological Departments of Târgu Mureş County Hospital. Materials and methods: We examined data obtained from hospitalized Parkinson’s disease patients during a 15-year period. According to the duration of the disease we split the patients into two groups, patients with Parkinson’s disease for less than or equal to 5 years and patients with disease duration longer than 5 years, and then analyzed only the former group. Results: During the examined period, 2,379 patients with Parkinson’s disease were hospitalized, and 1,237 patients had a disease duration shorter than 5 years. In this group, 18 patients had monoamine oxidase inhibitor monotherapy. Also, 665 patients received dopamine agonists, in 120 cases as monotherapy and in 83 patients associated with monoamine oxidase inhibitors. In 521 patients we found only levodopa treatment. A further 481 patients received combined therapy (levodopa with dopamine agonists and/or monoamine oxidase inhibitors). Conclusion: Treatment strategies for the early stages of Parkinson’s disease in our group were comparable to results from other studies. However, the authors feel that neurologists should use levodopa-sparing drugs with greater courage. Furthermore, if the clinical context is appropriate, physicians should combine substitution therapy with other antiparkinsonian drugs in order to reduce levodopa doses. Keywords: Parkinson’s disease, levodopa, dopamine agonistSzász JAOrbán-Kis KConstantin VAPéter CBíró IMihály ISzegedi KBalla ASzatmári SDove Medical PressarticleParkinson’s diseaselevodopadopamin agonistNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 15, Pp 831-838 (2019) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Parkinson’s disease levodopa dopamin agonist Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 |
| spellingShingle |
Parkinson’s disease levodopa dopamin agonist Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Szász JA Orbán-Kis K Constantin VA Péter C Bíró I Mihály I Szegedi K Balla A Szatmári S Therapeutic strategies in the early stages of Parkinson’s disease: a cross-sectional evaluation of 15 years’ experience with a large cohort of Romanian patients |
| description |
József Attila Szász,1,2 Károly Orbán-Kis,1 Viorelia Adelina Constantin,2,3 Csongor Péter,1 István Bíró,1 István Mihály,1,2 Kinga Szegedi,2 Antal Balla,2 Szabolcs Szatmári1,2 1University of Medicine and Pharmacy, Târgu Mureş, Romania; 22nd Neurology Department, Târgu Mureş County Emergency Hospital, Târgu Mureş, Romania; 3Doctoral School, Victor Babes University of Medicine and Pharmacy, Timişoara, Romania Introduction: In patients older than 70 years there is no valid alternative to progressively introduced substitution therapy. The antiparkinsonian drugs introduced in the last decade to treat Parkinson’s disease, especially in its early phases, promised a comparable efficacy in reducing symptoms to levodopa. In younger patients and/or patients with mild symptoms we hoped to delay the motor complications by postponing the start of levodopa therapy. While these assumptions may not be true for all patients, probably the most important current challenge is the optimal starting moment of levodopa therapy. The aim of the study was to analyze the therapeutical choices during the early phase of Parkinson’s disease in the Neurological Departments of Târgu Mureş County Hospital. Materials and methods: We examined data obtained from hospitalized Parkinson’s disease patients during a 15-year period. According to the duration of the disease we split the patients into two groups, patients with Parkinson’s disease for less than or equal to 5 years and patients with disease duration longer than 5 years, and then analyzed only the former group. Results: During the examined period, 2,379 patients with Parkinson’s disease were hospitalized, and 1,237 patients had a disease duration shorter than 5 years. In this group, 18 patients had monoamine oxidase inhibitor monotherapy. Also, 665 patients received dopamine agonists, in 120 cases as monotherapy and in 83 patients associated with monoamine oxidase inhibitors. In 521 patients we found only levodopa treatment. A further 481 patients received combined therapy (levodopa with dopamine agonists and/or monoamine oxidase inhibitors). Conclusion: Treatment strategies for the early stages of Parkinson’s disease in our group were comparable to results from other studies. However, the authors feel that neurologists should use levodopa-sparing drugs with greater courage. Furthermore, if the clinical context is appropriate, physicians should combine substitution therapy with other antiparkinsonian drugs in order to reduce levodopa doses. Keywords: Parkinson’s disease, levodopa, dopamine agonist |
| format |
article |
| author |
Szász JA Orbán-Kis K Constantin VA Péter C Bíró I Mihály I Szegedi K Balla A Szatmári S |
| author_facet |
Szász JA Orbán-Kis K Constantin VA Péter C Bíró I Mihály I Szegedi K Balla A Szatmári S |
| author_sort |
Szász JA |
| title |
Therapeutic strategies in the early stages of Parkinson’s disease: a cross-sectional evaluation of 15 years’ experience with a large cohort of Romanian patients |
| title_short |
Therapeutic strategies in the early stages of Parkinson’s disease: a cross-sectional evaluation of 15 years’ experience with a large cohort of Romanian patients |
| title_full |
Therapeutic strategies in the early stages of Parkinson’s disease: a cross-sectional evaluation of 15 years’ experience with a large cohort of Romanian patients |
| title_fullStr |
Therapeutic strategies in the early stages of Parkinson’s disease: a cross-sectional evaluation of 15 years’ experience with a large cohort of Romanian patients |
| title_full_unstemmed |
Therapeutic strategies in the early stages of Parkinson’s disease: a cross-sectional evaluation of 15 years’ experience with a large cohort of Romanian patients |
| title_sort |
therapeutic strategies in the early stages of parkinson’s disease: a cross-sectional evaluation of 15 years’ experience with a large cohort of romanian patients |
| publisher |
Dove Medical Press |
| publishDate |
2019 |
| url |
https://doaj.org/article/b5401913058d40abbaf589a699d9b6ee |
| work_keys_str_mv |
AT szaszja therapeuticstrategiesintheearlystagesofparkinsonrsquosdiseaseacrosssectionalevaluationof15nbspyearsrsquoexperiencewithalargecohortofromanianpatients AT orbankisk therapeuticstrategiesintheearlystagesofparkinsonrsquosdiseaseacrosssectionalevaluationof15nbspyearsrsquoexperiencewithalargecohortofromanianpatients AT constantinva therapeuticstrategiesintheearlystagesofparkinsonrsquosdiseaseacrosssectionalevaluationof15nbspyearsrsquoexperiencewithalargecohortofromanianpatients AT peterc therapeuticstrategiesintheearlystagesofparkinsonrsquosdiseaseacrosssectionalevaluationof15nbspyearsrsquoexperiencewithalargecohortofromanianpatients AT biroi therapeuticstrategiesintheearlystagesofparkinsonrsquosdiseaseacrosssectionalevaluationof15nbspyearsrsquoexperiencewithalargecohortofromanianpatients AT mihalyi therapeuticstrategiesintheearlystagesofparkinsonrsquosdiseaseacrosssectionalevaluationof15nbspyearsrsquoexperiencewithalargecohortofromanianpatients AT szegedik therapeuticstrategiesintheearlystagesofparkinsonrsquosdiseaseacrosssectionalevaluationof15nbspyearsrsquoexperiencewithalargecohortofromanianpatients AT ballaa therapeuticstrategiesintheearlystagesofparkinsonrsquosdiseaseacrosssectionalevaluationof15nbspyearsrsquoexperiencewithalargecohortofromanianpatients AT szatmaris therapeuticstrategiesintheearlystagesofparkinsonrsquosdiseaseacrosssectionalevaluationof15nbspyearsrsquoexperiencewithalargecohortofromanianpatients |
| _version_ |
1718400974224097280 |